Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790374 · ClinicalTrials.gov registry record · Phase 1
BN83495 in Prostate Cancer
A Phase 1 study, sponsored by Ipsen.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00790374 is a Phase 1 study that has completed, run by Ipsen. The registered enrollment target is 17 participants.
The verdict
NCT00790374, a Phase 1 study, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the pharmacodynamic profile and safety of BN83495 in patients with prostate cancer with disease progression while on androgen ablative therapy
Interventions
- DRUG BN83495 (Cohort 1)
- DRUG BN83495 (Cohort 2)
- DRUG BN83495 (Cohort 3)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00790374
The ClinicalTrials.gov registry entry for NCT00790374 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BN83495 (Cohort 1) is the first listed.
NCT00790374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00790374 about?
NCT00790374 is a clinical study titled "BN83495 in Prostate Cancer". The purpose of the study is to evaluate the pharmacodynamic profile and safety of BN83495 in patients with prostate cancer with disease progression while on androgen ablative therapy
What is the current status of trial NCT00790374?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2009-01. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00790374?
The interventions under investigation include: BN83495 (Cohort 1) (DRUG), BN83495 (Cohort 2) (DRUG), BN83495 (Cohort 3) (DRUG).
Who is sponsoring clinical trial NCT00790374?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.